As seen in PBMCs from B cell sufficient GPA patients, rituximab resulted in a significant downregulation of CD16 on NK cells compared to infliximab or the control without therapeutic antibody (Fig. 4d). This evidence concerns the gene FCGR3A and granulomatosis with polyangiitis.